Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL

NCT07301424 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)
BCR-ABL Positive Acute Lymphoblastic Leukemia

Interventions

DRUG: Treatment with blinatumomab given subcutaneously.

Sponsor

University of Alberta

Collaborators

[object Object]